Pacific RxTracts - July 2025

Abstract

Articles: First Blood Test Approved For the Diagnosis of Alzheimer’s Disease Rare Withdrawal Reaction Prompts Label Update for Common Antihistamines FDA Approves SUSVIMO: Shifting Diabetic Retinopathy Treatment from Monthly Injections to Continuous Therapy Battle Against Resistant Hypertension Two Is Better than One: Obicetrapib and Ezetimibe, a Novel Combination Pill for High Cholesterol Histo-blood Group ABO System Transferase and Venous Thromboembolism Risk GLP-1 Agonists and Thiazolidinedione Combination Therapy in Type 2 Diabetes Dual Pathway Targeting in Type 2 Diabetes: Exploring the Synergy of GLP1- RAs and SGLT2-inhibitors Two Vaccines, One Shot: Combined Immunizations Against COVID-19 and Influenza Mirikizumab: A New Frontier in Ulcerative Colitis Treatment Tocilizumab: A Better Way to Manage Rheumatoid Arthritis Oveporexton: A Novel Treatment Option for Narcolepsy Type I The Long-Term Effects of Ketamine on Treatment- Resistant Depression The First Targeted Therapy for a Rare Ovarian Cancer Vimseltinib Gains FDA Approval for Tenosynovial Giant Cell Tumour (TGCT) Hot Flashes No More Remote Clinical Pharmacists Drive Down Cancer Care Costs in Value-Based Model Camizestrant Takes Victory Lap After Phase 3 Trialshttps://scholarlycommons.pacific.edu/rx-tracts/1007/thumbnail.jp